Aberrant Motility in Unaffected Small Bowel is Linked to Inflammatory Burden and XXXX Symptoms in @entity30 .

@entity1 @entity32 @entity1190 @entity294 @entity29 @entity158 @entity4423 @entity30 @entity1319
BACKGROUND: Inflammation-related enteric @entity4423 has been postulated as a cause for abdominal symptoms in @entity30 ( @entity30 ). We investigated the relationship between magnetic resonance imaging-quantified @entity29 ( @entity29 ) motility, inflammatory activity, and @entity1 symptom burden. METHODS: The Harvey-Bradshaw index (HBI) and fecal calprotectin were prospectively measured in 53 @entity1 with @entity30 (median age, 35; range, 18-78 years) the day before magnetic resonance enterography, which included a dynamic (cine), breath-hold motility sequence, repeated to encompass the whole @entity29 volume. A validated registration-based motility quantitation technique produced motility maps, and regions of interest were drawn to include all morphologically normal @entity29 (i.e., excluding diseased bowel). @entity1319 was correlated with calprotectin, HBI, and symptom components (well-being, @entity158 , and @entity294 ). Adjustment for age, sex, smoking, and surgical history was made using multivariate linear regression. RESULTS: Median calprotectin was 336 (range, 0-1280). Median HBI, motility mean, and motility variance were 3 (range, 0-16), 0.33 (0.18-0.51), and 0.01 (0.0014-0.034), respectively. Motility variance was significantly negatively correlated with @entity1190 (rho = -0.33, P = 0.015), total HBI (rho = -0.45, P < 0.001), well-being (rho = -0.4, P = 0.003), @entity158 (rho = -0.27, P = 0.05), and @entity294 (rho = -0.4, P = 0.0025). The associations remained highly significant after adjusting for covariates. There was no association between mean motility and calprotectin or HBI (P > 0.05). CONCLUSIONS: Reduced motility variance in morphologically normal @entity29 is associated with @entity1 symptoms and fecal calprotectin levels, supporting the hypothesis that @entity32 -related enteric @entity4423 may explain refractory abdominal symptoms in @entity30 .
